<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351373</url>
  </required_header>
  <id_info>
    <org_study_id>19-005178</org_study_id>
    <nct_id>NCT04351373</nct_id>
  </id_info>
  <brief_title>Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560</brief_title>
  <official_title>Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine if there is benefit to using an IV contrast called
      AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular
      schwannoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgeon predicted use of FS in future cases</measure>
    <time_frame>Completion of surgical case, approximately 1 week</time_frame>
    <description>The primary outcome will be response to the question &quot;Based on the use and performance of FS in this case alone, how likely are you to use FS in future vestibular schwannoma cases (excluding the research trial)?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>differential measurement of red, green, and blue levels in VS tissue compared to the facial nerve and cochlear nerve</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>The first secondary endpoint is the differential measurement of red, green, and blue levels in VS tissue compared to the facial nerve and cochlear nerve using FS and YE560. ImageJ software will be used to analyze representative images capture from microsurgery. The operating surgeon will delineate regions of interest for the VS, facial nerve, and cochlear nerve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the time of tumor exposure, patients will be given intravenous fluorescein sodium. The timing and dose may vary. Maximum cumulative dose will not exceed 500 mg.
• Initial dosing protocol will be 1 mg/kg intravenous FS.
o If insufficient fluorescence is obtained or washout occurs, additional doses of 1 mg/kg may be administered
The surgeon will use the YELLOW 560 nm microscope filter (YE560) to assist in visualizing the tumor during the resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous fluorescein sodium</intervention_name>
    <description>Injection of IV FS during acoustic neuroma tumor removal</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YELLOW 560 nm microscope filter (YE560)</intervention_name>
    <description>The surgeon will utilize the microscope filter after the IV FS is administered</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patient with a suspected VS

          -  Recurrent VS with prior microsurgical resection or radiation therapy

          -  Clinical indication for microsurgical resection

        Exclusion Criteria

          -  Children (patients less than 18 years of age)

          -  History of allergy to FS

          -  History of renal failure

          -  Pregnant women

          -  Those with inability to give informed consent

          -  Prisoners and inmates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew L Carlson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Tombers, RN</last_name>
    <phone>507-284-8532</phone>
    <email>tombers.nicole@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Chan, MD</last_name>
    <email>chan.stephen@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew L. Carlson, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

